reason report
print unev biogen news sure pt
bottom line ac immun report earn
cash posit chf expect fund
oper overal number in-lin
expect think cash runway favor
updat financi model print result
materi chang howev given mp news
today reduc pt kept op
rate clearli neg aducanumab news today plu roch
discontinu cread trial late januari
good stock event nearli close door amyloid
hypothesi howev still think ac immun well posit
diversifi play alzheim particularli diversif strategi
clearli look even interest today compani pipelin
asset virtual fund larg partner thu littl cost
compani thank lilli deal last decemb compani
strong cash posit long runway late
could enabl intern develop new asset and/or pursuit new
next expect initi morphom tau phase studi
initi phase studi interim
data phase studi syndrom low
dose cohort high dose cohort data readout
anti-tau antibodi phase studi
sotp analysi forecast cash
flow discount
net debt total capit
year price history/av daili volume mil aciu
compani inform svb leerink llc research
revenu chf million
pleas refer page import disclosur price chart analyst certif
ac immun diversifi pipelin drug candid diagnost alzheim
diseas ad includ anti-tau antibodi morphom tau abeta vaccin
compani strong partner op anti-tau vaccin
mp alpha-synuclein-pet tracer diagnost lilli nr morphom tau
life molecular imag formerli piram imag tau-pet tracer diagnost
help valid project fund clinic develop expens program well
commerci product would result solid royalti stream success
ac immun also two proprietari drug discoveri platform one antibodi
small molecul strong knowledg base neurodegen diseas
enabl compani keep put new product pipelin
pt base sum-of-the-part sotp analysi forecast cash flow
discount rate
view ad trial riski biopharma therapeut area given numer
disappoint continu question whether amyloid hypothesi valid
anti-tau demonstr proof concept yet
mani compani pursu ad research
ac immun probabl need rais money continu fund project
start phase studi
ac immun revenu chf ad us ad ou antibodi ad us antibodi ad ou anti-abeta vaccin ad us anti-abeta vaccin ad ou anti-abeta vaccin syndrom us anti-abeta vaccin syndrom ou anti-tau vaccin ad us anti-tau vaccin ad ou tau pet tracer us tau pet tracer ou alpha-synuclein pet tracer us alpha-synuclein pet tracer ou morphom tau lilli us ou royalti royalti revenu milestonescrenezumab antibodi anti-abeta vaccin anti-abeta vaccin anti-tau vaccin -pet imag agent pet tracer pet ligand tdp growth factor morphom tau revenu mileston revenu royalti compani report svb leerink llc estim ac immun sa
ac immun balanc sheet chf asset receiv expens current asset stockhold equitycurr liabilitiesaccount current financ employe defin benefit equityshar comprehens stockhold liabil stockhold compani report svb leerink llc estim ac immun sa
ac immun chf oper activitiesnet result compens oper asset use oper invest activitiescapit invest use invest financ activitiesproce prefer seri chang common chang use financ equival begin equival end compani report svb leerink llc estim ac immun sa
marc goodman certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori ac immun sa aciu
leerink partner llc initi coverag aciu octob outperform rate
creat bluematrix
pt base sum-of-the-part sotp analysi forecast cash flow discount
risk valuat
view ad trial riski biopharma therapeut area given numer disappoint
continu question whether amyloid hypothesi valid
anti-tau demonstr proof concept yet
mani compani pursu ad research
ac immun probabl need rais money continu fund project
rate price target histori biogen inc
leerink place market perform rate februari
creat bluematrix
price target base simpl averag three approach believ reason
basi valu stock today approach price earn price sale dcf price earn
approach appli current multipl larg cap healthcar rhhbi sni
celg compani ep forecast produc one-year price target price
sale approach use current averag price sale slow grow larg cap biopharma stock celg
appli revenu forecast produc price target
lastli dcf take present valu forecast annual free cash flow
assum valu termin cash flow base termin growth rate discount compani
cost capit present valu averag approach current one-year price target
risk valuat
risk view outlook valuat includ major chang price reimburs
coverag label compani exist treatment multipl sclerosi tysabri avonex plegridi tecfidera
success develop rapid market share gain competitor product class success
gener challeng tecfidera intellectu properti posit alter ahead expect risk
includ disappoint question result on-going trial import develop program
particularli aducanumab opportun better perform valu includ strong result mid-
stage pipelin includ novel pain treatment vixotrigin anti-lingo myelin restor product opicinumab
success progress compani co-develop alzheim diseas treatment eisai ban
rate price target histori johnson johnson
leerink place outperform rate januari
creat bluematrix
next month believ share trade price target price target appli price-to-earnings
multipl ep estim share current trade ep estim
large-cap med-tech group rang price target assum
see multipl expans line broader comp group compani manag
top-lin headwind continu manag cost benefit actelion -- posit
sustain ep out-performance view total return capabl attract increasingli volatil
stock market environ like attract fund riskier area
risk valuat
risk includ failur success integr actelion amo synth potenti futur acquisit
failur resolv outstand consum consent decre success re-launch product product
recal failur advanc late-stag pipelin success launch new product protract recoveri
procedur volum trend lack real macroeconom recoveri
rate price target histori compani
leerink place outperform rate octob
creat bluematrix
sinc suspend coverag share longer put forth valuat
risk valuat
sinc suspend coverag longer put forth risk valuat
rate price target histori roch hold rhhbi
creat bluematrix
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
